Julie Rubinstein, who serves as President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), completed the sale of 38,120 shares of the companys common stock across transactions on April 1 and April 2, 2026. The disposition generated approximately $553,693 in proceeds, executed at weighted average prices in the range of $14.45 to $14.60 per share. As of the most recent trade, the shares are quoted at $14.81, representing an 86.5% gain over the prior 12 months.
In conjunction with the sales, Rubinstein exercised stock options on the same dates to acquire 29,444 shares of Adaptive Biotechnologies common stock at an exercise price of $7.27 per share, for an aggregate exercise cost of $214,057.
Independent analysis cited in company coverage indicates that, at current market levels, ADPT appears overvalued. The referenced research is available through a Pro Research Report that covers ADPT alongside a wide universe of U.S. equities.
Separately, Adeptus Biotechnologies Corp released its fourth-quarter 2025 results, delivering an earnings per share outcome of -$0.09, which exceeded the consensus forecast of -$0.18. The report characterized this as a 50% positive surprise relative to expectations. Revenue for the quarter came in at $71.7 million, topping the forecast of $59.33 million by 20.85%.
Following the quarter, several brokerages adjusted their targets and ratings. BTIG increased its price target for Adeptus Biotechnologies to $22.00 from $21.00, citing strong expansion in the companys core Minimal Residual Disease, or MRD, business, which grew 54% year over year in Q4 2025 and 46% for the full year. TD Cowen raised its target to $21.00 from $20.00. Piper Sandler reiterated an Overweight rating and maintained a $20.00 price target, highlighting the companys positioning in MRD testing for hematological malignancies. Collectively, these actions reflect positive analyst sentiment following the quarterly results.
This report focuses on the disclosed insider sales and option exercises at Adaptive Biotechnologies, the current market valuation commentary, and the latest quarterly performance and analyst responses for Adeptus Biotechnologies. The information on valuations and analyst assessments is presented as reported; investors seeking the underlying research and full reports are directed to the respective research services referenced.